StockNews.AISignal intelligence
Company intelligence

BIIB

Biogen Inc. · NASDAQ · Healthcare

Price$217.15+0.80% · +$1.72
Market cap32.08BEquity value
P / E13.7Trailing ratio
Volume1.08MLatest session
Market data

BIIB price chart

TradingView
Related signals
1 min delayed

Browse public BIIB signals with their source context and measured market impact. Open any signal for its permanent analysis page.

BIIBJul 14, 2026+2.80% since signal

Biogen-Eisai LEQEMBI IQLIK approval; diranersen Phase 2 data raises questions

Biogen and Eisai disclosed FDA approval for a weekly LEQEMBI IQLIK initiation regimen alongside Phase 2 diranersen data. While 18-month results show tau reductions and slowed decline across doses, the strongest effect occurred at 60 mg q6m, and questions about data robustness weighed on sentiment. The stock traded lower as investors weighed near-term risks against potential long-term Alzheimer's treatment opportunities.

View signal analysis
BIIBJul 13, 2026-7.71% since signal

FDA approves at-home starting dose for Leqembi, boosting access and uptake

The FDA cleared an at-home starting dose for Leqembi, enabling patients or caregivers to begin therapy outside clinics. This could lower initiation barriers and broaden eligible patients, potentially boosting near-term demand for the BIIB/Eisai drug. Realized uptake will hinge on payer reimbursement and how quickly the supply chain, training, and distribution scale.

View signal analysis
BIIBJun 17, 2026-1.05% since signal

Biogen to acquire RayThera for up to $1B, expanding immunology pipeline

Biogen announced it will acquire private RayThera for up to $1 billion, with upfront and milestone payments. The deal expands Biogen's immunology portfolio as RayThera's lead asset targets inflammatory diseases and begins Phase 1 in early Q3 2026, with Biogen steering development and commercialization after close in 3Q26. The acquisition adds near-term pipeline potential but carries integration and milestone risks.

View signal analysis
Research

Company intelligence